Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04744857
Other study ID # CSP12001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 13, 2019
Est. completion date October 16, 2020

Study information

Verified date February 2021
Source Peijia Medical Technology (Suzhou) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The TaurusOne® transcatheter aortic valve system with retrievable delivery catheter system is evaluated the safety and effectiveness for the delivery of artificial aortic valve in a prospective, multicenter, single-arm clinical trial.


Description:

The TaurusOne® transcatheter aortic valve system with retrievable delivery catheter system is evaluated the safety and effectiveness for the delivery of artificial aortic valve in a prospective, multicenter, single-arm clinical trial. According to the inclusion and exclusion criteria, sixty patients are planed been enrolled and implanted with TaurusOne® .Patients are seen at pre and post procedure, discharge, 30 days. The main follow-up included clinical symptoms and signs, cardiac ultrasound, CT, etc. The outcome included immediate device success, procedure success, And the major cardiovascular and cerebrovascular adverse events (MACCE, including mortality, stroke, myocardial infarction, reoperation, arrhythmia, conduction block).


Recruitment information / eligibility

Status Completed
Enrollment 85
Est. completion date October 16, 2020
Est. primary completion date October 16, 2020
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: - Patients who are willing to participate and sign the informed consent and can cooperate with the whole trial process; - Age =70 years old; - Patients with severe calcified aortic stenosis confirmed by echocardiography (trans-aortic valve flow velocity = 4.0m /s, or trans-active valvular pressure difference =40mmHg (1mmHg=0.133kPa), or aortic valve orientation area < 0.8cm2, or effective aortic valve orifice the product index is < 0.5cm2/m2); - Appear obvious symptoms caused by aortic stenosis, NYHA class ? or higher; - The cardiac team (at least two specialists in cardiovascular surgery) assessed the patient as unsuitable for routine surgery ; - The life expectancy of the patient after implantation of the prosthetic valve was evaluated by the cardiac team (at least two specialists in cardiovascular surgery) as more than one year; - Patients with aortic ring diameter =18mm and =29mm (cardiac CT measurement); - The diameter of the ascending aorta of the patient was < 50mm. Exclusion Criteria: - Patients with bacteremia or toxemia; - previous history or active endocarditis; - Acute myocardial infarction (Q-wave MI, or non-Q-wave MI with increased creatine kinase isoenzyme and/or troponin T) within 30 days; - Echocardiography found any intracardiac mass, left ventricle or atrial thrombosis, vegetations; - Symptomatic atrial fibrillation that cannot be improved by medication; - Familial hypertrophic cardiomyopathy; - Mitral valve and tricuspid valve insufficiency (reflux ? level above); - Prior aortic valve grafts (mechanical or biological valve stents); - Known allergy to contrast agent, aspirin, heparin, ticlopidine, nickel-titanium memory alloy, or bovine products; - Known to be contraindication or allergic to all anticoagulant regimens, or unable to use anticoagulant during the test; - Other serious diseases that may reduce life expectancy to less than 12 months (e.g. clinically recurrent or metastatic cancer, congestive heart failure, etc.) - Current drug abuse problem (e.g., alcohol, cocaine, heroin, etc.); Plan to undergo surgery that may cause nonadherence to protocol or confusion in data interpretation. - Cerebrovascular accident (CVA) in the past 6 months; - Patients with common or internal carotid or vertebral artery stenosis (> 70%); - WBC count < 3×109/L, platelet count < 50×109/ L; - Hemoglobin < 90g/L; - Patients with severe coagulation dysfunction; - Severe left ventricular dysfunction, left ventricular ejection fraction < 20%; - Abdominal or thoracic aortic aneurysm; - Hepatic encephalopathy or acute active hepatitis; - Receiving dialysis or a baseline creatinine level of > 3.0 mg/dL (266µmol/L); - Have bleeding tendency or history of coagulation disease or refuse blood transfusion; - Have active gastric ulcer or active gastrointestinal (GI) bleeding; - Suffer from neurological diseases that seriously affect the ability to move or live in daily life; - People with mental illness or mental disorder who cannot express themselves normally; - Need emergency surgery for any reason; - Screening participants who had participated in other drug or medical device clinical trials within the previous 3 months; - Other conditions considered by the investigator to be inappropriate for participation in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
Using the grip-loading system, the artificial aortic valve was squeezed and loaded into the sheath of the transporter through the vascular approach.The artificial aortic valve is delivered and positioned at the correct anatomical position for release. For example, the artificial main valve is displayed after partial release If the aortic valve is not in the correct anatomical position, the artificial aortic valve can be recovered and placed into the sheath tube of the transporter for re-positioning and release.

Locations

Country Name City State
China Peiga Medical Technology (Suzhou) Co., Ltd Suzhou Jiangsu

Sponsors (13)

Lead Sponsor Collaborator
Peijia Medical Technology (Suzhou) Co., Ltd. Air Force Military Medical University, China, Beijing Anzhen Hospital, Central South University, China National Center for Cardiovascular Diseases, Fu Wai Hospital, Beijing, China, General Hospital of Shenyang Military Region, Guangdong Provincial People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai Lingshi Medical Technology Co., Ltd, Shanghai Zhongshan Hospital, The Second Affiliated Hospital of Harbin Medical University, West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Product performance evaluation Product Performance includes grip loading, emptying , delivery, release, retrace, development and retrieval performance of delivery catheter system. Every item measured by:1=good 2=average 3=poor. Immediately after procedure
Other operative complication The rate of operative complication Immediately after procedure
Other The incidence of major adverse cardiovascular and cerebrovascular events during the trial(MACCEs) Incidence of MACCEs (including mortality, stroke, myocardial infarction, and so on surgery, arrhythmias, conduction blocks) during the trial. 30 days after procedure
Other Incidence of major adverse valvular events (MAVREs) during the trial Incidence of MAVREs (including artificial aortic valve-related death, permanent cardiac pacemaker or defibrillator implantation, artificial aortic valve embolism or thrombosis, artificial aortic valve loss of function) during the trial. 30 days after procedure
Other hemorrhage Rate of patients with hemorrhage during the trial. 30 days after procedure
Other acute kidney injury Rate of patients with acute kidney injury during the trial. 30 days after procedure
Other Other TAVI related complications Rate of patients with Other TAVI related complications during the trial. Other TAVI related complications include conversion to surgery, accidental cardiopulmonary mechanical assistance, coronary occlusion, ventricular septal perforation, mitral valve damage or loss of function, pericardial tamponade, endocarditis, valvular thrombosis, valvular ectopic (displacement, embolization, erroneous release), etc. 30 days after procedure
Other Valvular function Valvular function include valve stenosis, valve regurgitation, valve function (such as opening area, pressure gradient), perivalvular leakage, etc. 30 days after procedure
Primary Composite event rate at 30 days Patient-oriented composite event including all-cause death,severe stroke,myocardial infarction, permanent pacemaker implantation,surgical reoperation and valve-in-valve. 30 days after procedure
Secondary Device success rate (immediately after procedure) Device success is defined as
Vascular access, artificial aortic valve delivery and release were successful, and the delivery catheter was successfully withdrawn.
The artificial aortic valve was implanted in an anatomically accurate position.
The artificial aortic valve met the expected requirements (mean transvalvular pressure difference < 20mmHg or maximum flow rate < 3m/s; No serious manual initiative valve regurgitation or perivalvular leakage)
Immediately after procedure
Secondary Procedure success rate Procedure success is defined as the artificial aortic valve successfully implanted in the correct anatomical position 72h after surgery or before discharge without severe artificial aortic valve regurgitation or perivalvular leakage. 72 hours after procedure/prior to discharge
Secondary Cardiac function improvement Cardiac function improvement is accessed by NYHA cardiac function classification increases from baseline to 30 days. 30 days after procedure
Secondary Quality of life of patients Quality of Life of patients accessed by EuroQol-5 Dimensions (EQ-5D) Questionnaire. The higher scores mean a worse health state. Recording changes from baseline to 30 days. 30 days after procedure
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01676727 - ADVANCE Direct Aortic Study
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Terminated NCT05070130 - OpSens PRIME CLASS
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A